Goldman Sachs Group Inc Merrimack Pharmaceuticals Inc Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Merrimack Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 29,807 shares of MACK stock, worth $450,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,807
Previous 14,471
105.98%
Holding current value
$450,979
Previous $213,000
111.27%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MACK
# of Institutions
7Shares Held
429KCall Options Held
0Put Options Held
0-
Jbf Capital, Inc. Aspen, CO39.6KShares$599,7070.1% of portfolio
-
Marshall Wace, LLP London, X038.2KShares$578,2830.0% of portfolio
-
Rhumbline Advisers Boston, MA2.48KShares$37,5220.0% of portfolio
-
Rise Advisors, LLC272Shares$4,1150.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA77Shares$1,1650.0% of portfolio
About MERRIMACK PHARMACEUTICALS INC
- Ticker MACK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,410,200
- Market Cap $203M
- Description
- Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.